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Background: A malfunction of RXRα due to phosphorylation is associated with liver carcinogenesis, and acyclic
retinoid (ACR), which targets RXRα, can prevent the development of hepatocellular carcinoma (HCC). Activation of
PI3K/Akt signaling plays a critical role in the proliferation and survival of HCC cells. The present study examined the
possible combined effects of ACR and LY294002, a PI3K inhibitor, on the growth of human HCC cells.
Methods: This study examined the effects of the combination of ACR plus LY294002 on the growth of HLF human
HCC cells.
Results: ACR and LY294002 preferentially inhibited the growth of HLF cells in comparison with Hc normal hepatocytes.
The combination of 1 μM ACR and 5 μM LY294002, in which the concentrations used are less than the IC50 values of
these agents, synergistically inhibited the growth of HLF, Hep3B, and Huh7 human HCC cells. These agents when
administered in combination acted cooperatively to induce apoptosis in HLF cells. The phosphorylation of RXRα, Akt,
and ERK proteins in HLF cells were markedly inhibited by treatment with ACR plus LY294002. Moreover, this
combination also increased RXRE promoter activity and the cellular levels of RARβ and p21CIP1, while decreasing the
levels of cyclin D1.
Conclusion: ACR and LY294002 cooperatively increase the expression of RARβ, while inhibiting the phosphorylation of
RXRα, and that these effects are associated with the induction of apoptosis and the inhibition of cell growth in human
HCC cells. This combination might therefore be effective for the chemoprevention and chemotherapy of HCC.
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Retinoids, vitamin A metabolites and analogs, are ligands of
the nuclear receptor superfamily that exert fundamental ef-
fects on cellular activities, including growth, differentiation,
and death (regulation of apoptosis). Retinoids exert their
biological functions primarily by regulating gene expression
through 2 distinct nuclear receptors, the retinoic acid
receptors (RARs) and retinoid X receptors (RXRs), which
are ligand-dependent transcription factors [1,2]. Among
retinoid receptors, RXRs are regarded as master regulators
of the nuclear receptor superfamily because they play an
essential role in controlling normal cell proliferation and* Correspondence: shimim-gif@umin.ac.jp
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reproduction in any medium, provided the ormetabolism by acting as common heterodimerization
partners for various types of nuclear receptors [1,2]. There-
fore, altered expression and function of RXRs are strongly
associated with the development of various disorders,
including cancer, whereas targeting RXRs by retinoids
might be an effective strategy for the prevention and
treatment of human malignancies [3].
Hepatocellular carcinoma (HCC) is one of the most
frequently occurring cancers worldwide. Recent studies
have revealed that a malfunction of RXRα, one of the
subtypes of RXR, due to aberrant phosphorylation by the
Ras/mitogen-activated protein kinase (MAPK) signaling
pathway is profoundly associated with liver carcinogenesis
[4-9]. On the other hand, a prospective randomized study
showed that administration of acyclic retinoid (ACR), ad. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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opment of a second primary HCC, and thus improved
patient survival from this malignancy [10,11]. ACR inhibits
the growth of HCC-derived cells via the induction of apop-
tosis by working as a ligand for retinoid receptors [12,13].
ACR also suppresses HCC cell growth and inhibits the
development of liver tumors by inhibiting the activation
and expression of several types of growth factors and their
corresponding receptor tyrosine kinases (RTKs), which lead
to the inhibition of the Ras/MAPK activation and RXRα
phosphorylation [8,9,14-17]. These reports strongly suggest
that ACR might be a promising agent for the prevention
and treatment of HCC.
Phosphatidylinositol 3-kinase (PI3K) is activated by
growth factor stimulation through RTKs and Ras activa-
tion, and plays a critical role in cell survival and prolifera-
tion in collaboration with its major downstream effector
Akt, a serine-threonine kinase [18-20]. Increasing evi-
dence has shown that aberrant activation of the PI3K/Akt
pathway is implicated in the initiation and progression of
several types of human malignancies, including HCC,
indicating that targeting PI3K/Akt signaling might be an
effective strategy for the treatment of cancers [18-22].
Several clinical trials have been conducted to investigate
the safety and anti-cancer effects of therapeutic agents
that inhibit the PI3K/Akt signaling cascade [18-20].
Combined treatment with a PI3K/Akt inhibitor and other
agents, including MAPK inhibitors, might also be a
promising regimen that exerts potent anti-cancer proper-
ties [23,24].
Combination therapy and prevention using ACR as a key
drug is promising for HCC treatment because ACR can act
synergistically with other agents in suppressing growth and
inducing apoptosis in human HCC-derived cells [17,25-30].
The aim of the present study is to investigate whether the
combination of ACR plus LY294002, a PI3K inhibitor,
exerts synergistic growth inhibitory effects on human HCC
cells, and to examine possible mechanisms for such syn-
ergy, predominantly focusing on the inhibitory effects on
RXRα phosphorylation by a combination of these agents.
Methods
Materials
ACR (NIK-333) was supplied by Kowa Pharmaceutical
(Tokyo, Japan). LY294002 was purchased from Wako
(Osaka, Japan). Another PI3K inhibitor NVP-BKM120
(BKM120) was from Selleck Chemicals (Houston, TX,
USA).
Cell lines and cell culture conditions
HLF, Huh7, Hep3B, and HepG2 human HCC cell lines were
obtained from the Japanese Cancer Research Resources
Bank (Tokyo, Japan) and were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%FCS and 1% penicillin/streptomycin. The Hc human normal
hepatocyte cell line was purchased from Cell Systems
(Kirkland, WA, USA) and maintained in CS-S complete
medium (Cell Systems). These cells were cultured in an
incubator with humidified air containing 5% CO2 at 37°C.
Cell proliferation assays
Three thousand HCC (HLF, Huh7, Hep3B, and HepG2) or
Hc cells were seeded on 96-well plates in serum-free
medium. Twenty-four hours later, the cells were treated
with the indicated concentrations of ACR or LY294002 for
48 hours in DMEM supplemented with 1% FCS. Cell prolif-
eration assays were performed using a MTS assay (Promega,
Madison, WI, USA) according to the manufacturer’s instruc-
tions. The combination index (CI)-isobologram was used to
determine whether the combined effects of ACR plus
LY294002 were synergistic [25,27,30,31]. HLF cells were also
treated with a combination of the indicated concentrations
of ACR and BKM120 for 48 hours to examine whether
this combination synergistically inhibited the growth of
these cells.
Apoptosis assays
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) and caspase-3 activity assays
were conducted to evaluate apoptosis. For the TUNEL assay,
HLF cells (1 × 106), which were treated with 1 μM
ACR alone, 5 μM LY294002 alone, or a combination
of these agents for 48 hours, were stained with TUNEL
methods using an In Situ Cell Death Detection Kit,
Fluorescein (Roche Diagnostics, Mannheim, Germany) [25].
The caspase-3 activity assay was performed using HLF cells
that were treated with the same concentrations of the test
drugs for 72 hours. The cell lysates were prepared and the
caspase-3 activity assay was performed using an Apoalert
Caspase Fluorescent Assay Kit (Clontech Laboratories,
Mountain View, CA, USA) [30].
Protein extraction and western blot analysis
Protein extracts were prepared from HLF cells treated
with 1 μM ACR alone, 5 μM LY294002 alone, or a com-
bination of these agents for 12 hours because this treat-
ment time was appropriate for evaluating the expression
levels of phosphorylated extracellular signal-regulated
kinase (p-ERK), phosphorylated Akt (p-Akt), and phos-
phorylated RXRα (p-RXRα) proteins [25,29,30]. Equivalent
amounts of extracted protein were examined by western
blot analysis using specific antibodies [25]. The anti-
RXRα and anti-RARβ antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The primary anti-
bodies for ERK, p-ERK, Akt, p-Akt, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) were from Cell
Signaling Technology (Beverly, MA, USA). The antibody
for p-RXRα was kindly provided by Drs. S. Kojima
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Saitama, Japan).
RNA extraction and quantitative RT-PCR analysis
Total RNA was isolated from HLF cells using an
RNAqueous-4PCR kit (Ambion Applied Biosystems, Austin,
TX, USA) and cDNA was amplified from 0.2 μg of total
RNA using the SuperScript III Synthesis system (Invitrogen,
Carlsbad, CA, USA) [32]. Quantitative real-time reverse
transcription PCR (RT-PCR) analysis was performed using
specific primers that amplify the RARβ, p21CIP1, cyclin D1,
and β-actin genes. The specific primer sets used have been
described elsewhere [25,30].
RXRE reporter assays
HLF cells were transfected with RXR-response element
(RXRE) reporter plasmids (100 ng/well in 96-well dish),
which were kindly provided by the late Dr. K. Umesono
(Kyoto University, Kyoto, Japan), along with pRL-CMV
(Renilla luciferase, 10 ng/well in 96-well dish; Promega) as
an internal standard to normalize transfection efficiency.
Transfections were carried out using Lipofectamine LTX
Reagent (Invitrogen). After exposure of cells to the transfec-
tion mixture for 24 hours, the cells were treated with 1 μM
ACR alone, 5 μM LY294002 alone, or a combination of
these agents for 24 hours. The cell lysates were then
prepared, and the luciferase activity of each cell lysate was
determined using a dual-luciferase reporter assay system
(Promega) [25].
Statistical analysis
The data are expressed in terms of means ± SD. The
statistical significance of the differences in the mean
values was assessed using one-way ANOVA, followed by
Tukey-Kramer multiple comparison tests. Values of <0.05
were considered significant.Figure 1 Inhibition of cell growth by ACR and LY294002 in HLF huma
treated with the indicated concentrations of ACR (A) or LY294002 (B) for 4
as a percentage of the control value. Error bars present the SD of triplicateResults
ACR and LY294002 cause preferential inhibition of growth
in HLF human HCC cells in comparison with Hc normal
hepatocytes
In the initial study, the growth inhibitory effect of ACR
and LY294002 on HLF human HCC cells and on Hc
hepatocytes was examined. ACR (Figure 1A) and LY294002
(Figure 1B) inhibited the growth of HLF cells with IC50
values of approximately 6.8 μM and 15 μM, respectively.
On the other hand, Hc cells were resistant to these agents
because the IC50 values of ACR and LY294002 for the
growth inhibition of Hc cells were each greater than 50 μM
(Figure 1). These results suggest that ACR and LY294002
preferentially inhibit the growth of HCC cells compared
with that of normal hepatocytes.
ACR along with LY294002 causes synergistic inhibition of
growth in HCC cells
Next, the effects of the combined treatment of ACR plus
LY294002 on the growth of HCC-derived cells and Hc
hepatocytes were examined. When HLF human HCC cells
were treated with a range of concentrations of these agents,
the CI indices for less than 1 μM ACR (0.5 or 1 μM) plus
less than 10 μM LY294002 (5 or 10 μM) were 1+ (slight
synergism), 2+ (moderate synergism), or 3+ (synergism). In
particular, the combination of as little as 1 μM ACR
(approx. IC15 value) and 5 μM LY294002 (approx. IC25
value) exerted synergistic growth inhibition because the CI-
isobologram analysis yielded a CI index of 0.54 (3+), which
indicates synergism [25,27,30,31], with this combination
(Figure 2A,B, and Table 1). In other HCC cell lines, includ-
ing Huh7, Hep3B, and HepG2 cell lines, similar findings
were also obtained using Huh7 and Hep3B cells; the
combination of 1 μM ACR plus 5 μM LY294002 signifi-
cantly suppressed the growth of these cells (Figure 2C). In
contrast, the growth of Hc normal hepatocytes was not
affected by the combination of these agents; even an HCC cells and Hc normal hepatocytes. HLF and Hc cells were
8 hours. Cell viability was determined by the MTS assay and expressed
assays.
Figure 2 (See legend on next page.)
Baba et al. BMC Cancer 2013, 13:465 Page 4 of 11
http://www.biomedcentral.com/1471-2407/13/465
(See figure on previous page.)
Figure 2 Inhibition of cell growth by ACR alone, LY294002 alone, or various combinations of these agents in human HCC-derived cells
and Hc normal hepatocytes. (A) HLF human HCC cells were treated with the indicated concentrations of ACR alone, LY294002 alone, and various
combinations of these agents for 48 hours. (B) The data obtained in (A) was used to calculate the combination index. (C) Huh7, Hep3B, and
HepG2 human HCC cells were treated with vehicle, 1 μM ACR alone, 5 μM LY294002 alone, or a combination of 1 μM ACR and 5 μM LY294002 for
48 hours. (D) Hc human hepatocytes were treated with the indicated concentrations of ACR alone, LY294002 alone, and various combinations of
these agents for 48 hours. (A), (C), and (D) Cell viability was determined by the MTS assay and expressed as a percentage of the control value.
Error bars present the SD of triplicate assays. * P < 0.05.
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LY294002 (15 μM) did not inhibit the growth of Hc cells in
the present study (Figure 2D).
ACR plus BKM120 cause synergistic inhibition of growth
in HLF cells
In order to examine whether PI3K inhibitors are promis-
ing agents to potently suppress the growth of HCC cells
in conjunction with ACR, the combined effects of ACR
plus BKM120, another selective PI3K inhibitor [33], on
the growth of HLF cells were next investigated. The
combination of ACR plus BKM120 significantly inhibited
the growth of HLF cells. In particular, when the cells were
treated with 1 μM ACR plus 5 μM BKM120, the CI-
isobologram analysis yielded a CI-index of 3+ (synergism)
(Figure 3A,B, and Table 1). These findings suggest that
combination therapy using ACR plus PI3K inhibitors
might be an effective regimen for inhibiting the growth of
HCC cells.
ACR plus LY294002 cooperatively induce apoptosis in
HLF cells
The next study examined whether the synergistic growth
inhibition in HLF cells induced by treatment with ACR plus
LY294002 is associated with the induction of apoptosis.
The ratio of TUNEL-positive cells was not significantly
increased by treatment with 1 μM ACR alone (26.9%) or








“-”, CI1.1-1.3 moderate antagonism;
“±”, CI0.9-1.1 additive effect;
“+”, CI0.8-0.9 slight synergism;
“++”, CI0.6-0.8 moderate synergism;
“+++”, CI0.4-0.6 synergism;
Abbreviations: CI Combination index, ACR Acyclic retinoid.control untreated cells (15.2%). However, when the cells
were treated with the combination of these agents,
TUNEL-positive cells significantly increased to 54.4% of the
total remaining cells (Figure 4A). Similar results were also
observed in the caspase-3 activity assay; the combined
treatment with ACR plus LY294002 significantly increased
the levels of caspase-3 activity in HLF cells, whereas treat-
ment with ACR alone or LY294002 alone did not exert
such an effect (Figure 4B).ACR plus LY294002 cooperatively suppress the
phosphorylation of RXRα, ERK, and Akt and increase the
RXRE promoter activity in HLF cells
RXRα phosphorylation is involved in the development
of HCC, and thus might be a promising target for
HCC chemoprevention [4-9]. Therefore, the effects of the
combination of ACR and LY294002 on the phosphorylation
of RXRα and related signaling molecules were next investi-
gated in HLF cells. As shown in Figure 5A, there was a
significant decrease in the expression levels of p-RXRα,
p-ERK, and p-Akt proteins when the cells were treated with
1 μM ACR. Treatment with 5 μM LY294002 also caused a
marked decrease in the expression levels of p-RXRα and
p-Akt proteins in these cells. Moreover, the decrease in the
expression levels of p-RXRα, p-ERK, and p-Akt proteins
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Figure 3 Inhibition of cell growth by ACR alone, BKM120 alone, or various combinations of these agents in HCC cells. (A) HLF human
HCC cells were treated with the indicated concentrations of ACR alone, BKM120 alone, or various combinations of these agents for 48 hours. Cell
viability was determined by the MTS assay and expressed as a percentage of the control value. (B) The data obtained in (A) was used to calculate
the combination index. Error bars present the SD of triplicate assays.
Figure 4 Effects of the combination of ACR and LY294002 on the induction of apoptosis in HLF cells. The cells were treated with vehicle,
1 μM ACR alone, 5 μM LY294002 alone, or a combination of 1 μM ACR and 5 μM LY294002 for 48 or 72 hours. (A) TUNEL assays were performed
using cells treated with test drugs for 48 hours. TUNEL-positive cells were counted and examined as the percentage of the DAPI-positive cell
number (500 cells were counted in each flask). (B) Caspase-3 activity assays were performed with a fluorometric system using samples treated for
72 hours. # P < 0.01. * P < 0.05.
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Figure 5 Effects of the combination of ACR and LY294002 on the phosphorylation of RXRα, ERK, and Akt proteins and the
transcriptional activity of the RXRE promoter in HLF cells. (A) The cells were treated with vehicle, 1 μM ACR alone, 5 μM LY294002 alone, or
a combination of 1 μM ACR and 5 μM LY294002 for 12 hours. The extracted proteins were examined by western blot analysis using the
respective antibodies. Repeat western blots gave similar results. (B) A transient transfection reporter assay was performed with the RXRE luciferase
reporter in the presence of vehicle, 1 μM ACR alone, 5 μM LY294002 alone, or a combination of 1 μM ACR and 5 μM LY294002. Relative luciferase
activity was determined after 24 hours. Columns and lines indicate the means and SD of triplicate assays. # P < 0.01. * P < 0.05.
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transcriptional activity of the RXRE reporter when HLF
cells were treated with a combination of ACR and
LY294002, whereas treatment with the same concentra-
tions of ACR alone or LY294002 alone did not upregulate
the activity of this promoter (Figure 5B). Because RXRs
modulate the expression of target genes by interacting
with the RXRE element located in the promoter regions of
these genes [1,2], this finding may indicate that LY294002
enhances the transcriptional activity of the RXRE pro-
moter induced by ACR, at least in part by inhibiting the
phosphorylation of RXRα.
ACR and LY294002 cooperatively increase the cellular levels
of RARβ and p21CIP1, but decrease the levels of cyclin D1, in
HLF cells
Because the transcriptional activity of the RXRE promoter
was significantly increased by treatment with ACR plus
LY294002 (Figure 5B), the next study examined whether
this combination cooperatively altered the expression of
target molecules of ACR, including RARβ, p21CIP1, and
cyclin D1 [13,25,27,34], in HLF cells. As shown in
Figure 6A, the mRNA and protein expression levels of
RARβ were significantly increased on combined treatment
with ACR and LY294002. Quantitative RT-PCR analyses
also revealed that there was a significant increase in the
levels of p21CIP1 mRNA, but a decrease in the levels of
cyclin D1 mRNA, in HLF cells, upon treatment with this
combination (Figure 6B).
Discussion and conclusions
In order to improve the clinical outcome for patients
with HCC, development of effective strategies for the
chemoprevention and chemotherapy of this malignancy isurgently required. We believe that combination chemo-
prevention using ACR as a key agent is a promising
method for attaining this objective, because it provides an
opportunity to take advantage of the synergistic effects of
ACR on growth inhibition in HCC cells [17,25-30]. The
present study provides the first evidence that the combin-
ation of ACR with LY294002, a PI3K inhibitor, synergistic-
ally inhibited the growth of human HCC cells through the
induction of apoptosis. Activation of the PI3K/Akt path-
way, which is common in many cancers such as HCC
[21,22], contributes to the inhibition of apoptosis and in-
duction of therapeutic resistance in cancer cells, indicating
that targeting this pathway can inhibit the survival and
growth of cancer cells through various mechanisms such
as potentiation of the effects of chemotherapeutic drugs
[18-20,23,24]. For instance, the combination of all-trans
retinoic acid with LY294002 enhanced growth suppressive
effects in leukemic cells by inducing apoptosis [35].
The hypotheses that explain the synergism generated by
the combination of ACR and LY294002 are summarized
in Figure 7. First, it should be noted that phosphorylation
of RXRα was markedly inhibited by the combination of
ACR and LY294002 in the present study. This finding
seems to be significant because RXRα phosphorylation
plays a role in the development of HCC and, therefore,
might be a critical target for the implementation of HCC
chemoprevention [5,7-9]. Accumulation of phosphory-
lated RXRα induced by the Ras/MAPK activation inter-
feres with the function of normal (unphosphorylated)
RXRα in a dominant negative manner [8,9]. This and prior
studies [4,17,25,28] show that ACR alone inhibits the
phosphorylation of RXRα and ERK proteins in HCC
cells. Moreover, in the present study, ACR alone also
dephosphorylated the Akt protein in HLF cells. These
Figure 6 Effects of the combination of ACR and LY294002 on the cellular expression levels of RARβ, p21CIP1, and cyclin D1 in HLF cells.
(A) The expression levels of RARβ mRNA (left panel) and protein (right panel) were examined by quantitative real-time RT-PCR analysis and western
blot analysis, respectively, using cells treated with the test drugs for 24 hours. (B) Quantitative real-time RT-PCR analysis to examine the expression
levels of p21CIP1 and cyclin D1 mRNAs were performed using cells treated with the test drugs for 24 hours. The expression level of each mRNA was
normalized to the level of β-actin mRNA. Values represent the means ± SD of triplicate analyses. * P < 0.05.
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LY294002 cooperatively inhibit the phosphorylation of
RXRα through dephosphorylation of ERK and Akt, which
leads to the synergistic inhibition of growth and the
induction of apoptosis in HCC cells. The results of the
present research, together with those of previous studies
[17,25,28-30], suggest that dephosphorylation of RXRα
might be a key mechanism for ACR-based combination
chemoprevention in HCC cells.
Phosphorylated RXRα loses its ability to form heterodimers
with RARβ and this is associated with resistance to
retinoids [7]. Therefore, restoration of the function of
RXRα by inhibiting its phosphorylation is critical to regu-
late the expression of retinoid target genes [4-9]. In com-
parison to treatment with ACR alone or LY294002 alone,
combined treatment with these agents significantly in-
creased the transcriptional activity of the RXRE reporter
in the present study. This combination also significantly
altered the expression levels of ACR target genes, such
as RARβ, p21CIP1, and cyclin D1 mRNA [13,25,27,34].
Particularly, the induction of RARβ by the combination of
ACR and LY294002 might play a crucial role in inhibiting
the growth of HCC cells because RARβ, which is a recep-
tor for ACR [36], can exert tumor-suppressive effects incancer cells and thus be considered as a tumor suppressor
gene [37].
In this study, the phosphorylation of Akt is inhibited by
ACR alone in HLF cells. This finding seems to be of interest
because Akt phosphorylation plays a critical role in cell
survival, prevention of apoptosis, and progression of cell
cycle in various types of tumors, including HCC [21,22].
The precise mechanism by which ACR inhibits the
phosphorylation of Akt protein has not been determined.
However, we assume that the dephosphorylation of this
protein by ACR might be explained by, at least in part, its
ability to inhibit growth factor-dependent RTK activity,
because Akt is potently phosphorylated by the activation of
RTKs [8,9,14,15,18-20]. For instance, ACR inhibits the
growth of HCC cells and prevents chemically induced liver
tumorigenesis by targeting the transforming growth factor-
α/epidermal growth factor receptor (EGFR) axis, which
belongs to RTKs [14,15]. Moreover, a recent study showed
that retinol inhibited PI3K activity by decreasing the inter-
action between PI3K and phosphatidylinositol and this was
associated with suppression of cell growth in colon cancer
cells [38]. These studies suggest that the PI3K/Akt signaling
pathway might be a critical target for retinoids to exert their
anti-cancer and chemopreventive properties.
Figure 7 A hypothetical schematic representation of the effects of the combination of ACR and LY294002 on growth inhibition in HCC
cells. When ACR binds to and activates RXRα, it forms homo- and/or heterodimers with other nuclear receptors (NRs), including RARs. This results
in the activation of the transcriptional activity of the responsive element, thus controlling the expression of the target genes, such as RARβ,
p21CIP1, and cyclin D1, which induce apoptosis and inhibit the growth of HCC cells (A). In HCC cells, the MAPK/ERK and PI3K/Akt pathways, both
of which are located downstream of Ras, are highly activated and phosphorylate the RXRα protein. The accumulation of phosphorylated RXRα
protein, which impairs dimer formation and the subsequent transactivation functions of this receptor, cause a deviation from normal cell
proliferation and differentiation, thereby playing a critical role in liver carcinogenesis (B). ACR and LY294002 inhibit RXRα phosphorylation by
inhibiting ERK and Akt phosphorylation, resulting in restoration of receptor function and activation of the transcriptional activity of the responsive
element (C). For additional details, see the Discussion section.
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LY294002 significantly inhibited the growth of HLF, Huh7,
and Hep3B HCC cells, whereas the growth of HepG2 cells,
the other HCC cell line, was not suppressed by this com-
bination. This might be associated with the phosphorylation
status of ERK and Akt proteins because the expression
levels of p-ERK and p-Akt proteins were increased in HLF,
Huh7, and Hep3B cells compared with HepG2 cells [29].
These results, on the other hand, suggest that HCC cells
that overexpress p-ERK and p-Akt proteins might be more
sensitive targets for combination therapy using ACR and
PI3K inhibitors.
Finally, it should be emphasized that combination
therapy and prevention are advantageous because, in
addition to providing the potential for synergistic effects,
they may reduce the opportunity for the development of
drug resistance by cancer cells. Several preclinical studies
have shown that cancer cells harboring activated Ras
mutations appear to be resistant to treatment with PI3K
inhibitor alone [23,39]. However, the use of a combination
of the PI3K/Akt inhibitor and a MAPK inhibitor signifi-
cantly exerted anti-cancer effects in Kars G12D-driven orEGFR-mutant lung tumors [23,24]. These studies suggest
that effective treatment with PI3K inhibitors require con-
comitant therapies that target RTK/Ras/MAPK signaling
and, therefore, ACR, which can inhibit this signaling
pathway [8,9,14,15,40], might be a preferable partner for
PI3K inhibitors.
In conclusion, the present study indicates that the
combination of ACR and LY294002, which can inhibit
the phosphorylation of RXRα, causes a synergistic induc-
tion of apoptosis and inhibition of cell growth in human
HCC cells. The results of our study suggest that this
combination might hold promise as a clinical modality
for the prevention and treatment of HCC, due to their
synergistic effects. In particular, our finding that the
combination regimen using 1 μM ACR plus 5 μM
LY294002 synergistically inhibits the growth of HCC
cells seems to be clinically relevant because this concen-
tration (1 μM) is approximately the same as the plasma
concentration of ACR (which ranged from 1 to 5 μM) in
a clinical trial that demonstrated the chemopreventive
effects of this agent in the recurrence of secondary HCC
[10,11].
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